FLT3 and acute myeloid leukemia: These findings are consistent with clinical data showing that treatment of FLT3/ITD positive AML patients with monotherapy with some FLT3 TKI has frequently given rise to blasts that express D835Y, rendering the cells insensitive to further therapy.